UCB

UCB SA Monitor

UCB SA Annual Report 2017
CR Monitor Issue: 
2018/0611
Company covered: 
UCB SA
Period End: 
31 December, 2017
Report issued on 19 June 2018 covered the following practice issues:
Pronouncements
Early adoption of IFRS 15 "Revenue from contracts with customers" using a full retrospective approach.
Pronouncements
Enhanced disclosure in respect of the future impacts of IFRS 16 "Leases".
Change
Fair value of previously held interest in business acquired taken into account in calculation of goodwill.
Pronouncements
Presentation of a reconciliation of movements in liabilities arising from financing activities on adoption of amendment to IAS 7 "Statement of cash flows".
Change
Discussion of key audit matters included in the auditors' report.
Change
Extended disclosure of principal risks including identification of a new risk factor.

Inventories - UCB SA

Period End: 
31 December, 2015
Period End Date: 
2015-12-31
Listing Status: 
S&P Europe 350
ICB Industry Classification: 
4573 Biotechnology
Auditor: 
PricewaterhouseCoopers

R&D tax and expenditure credits: an emerging issue under IFRS

This report addresses accounting for the new research and development (R&D) expenditure credit (RDEC) available from Her Majesty's Revenue and Customs (HMRC), the responsible tax authority in the United Kingdom, the previous UK scheme still in force for some companies and a similar scheme in Europe.

Accounting estimates and judgements - UCB

Period End: 
31 December 2014
Period End Date: 
2015-12-31
Listing Status: 
S&P Europe 350
ICB Industry Classification: 
4577 Pharmaceuticals
Auditor: 
PricewaterhouseCoopers
Annual Report: 

Revised definition of control in IFRS 10 "Consolidated financial statements": an emerging issue under IFRS

This report examines application of the revised definition of control in IFRS 10 “Consolidated financial statements”. We also take into consideration the guidance given by IFRS 10 to determine which companies fall within the scope of the Standard.

UCB SA Monitor

UCB SA Annual Report 2013
CR Monitor Issue: 
2014/0501
Company covered: 
UCB SA
Period End: 
31 December 2013
Report issued on 05 May 2014 covered the following practice issues:
Pronouncements
Extended scope of consolidation expected to reduce equity, operating profit and "net income".
Change
Reclassification of research and development tax credits increases pre-tax profit by 12%.
Change
Put and call option adjusted against consideration as business combination finalised.
Change
Disclosure of post balance sheet date marketing agreement.